Currently out of the existing stock ratings of Matthew Sykes, 84 are a HOLD (33.07%), 136 are a BUY (53.54%), 34 are a SELL (13.39%).

Matthew Sykes

Work Performance Price Targets & Ratings Chart

Analyst Matthew Sykes, carries an average stock price target met ratio of 66.67% that have a potential upside of 21.94% achieved within 216 days. Previously, Matthew Sykes worked at GOLDMAN SACHS, WILLIAM BLAIR.

Matthew Sykes’s has documented 492 price targets and ratings displayed on 41 stocks. The coverage was on Healthcare, Basic Materials, Industrials sectors.

Most recent stock forecast was given on TWST, Twist Bioscience Corp at 13-Nov-2025.

Wall Street Analyst Matthew Sykes

Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.

Average potential price target upside

DHR Danaher MRVI Maravai Lifesciences Holdings NAUT Nautilus Biotechnology NTRA Natera NVTA Invitae Corp PKI PerkinElmer TMO Thermo Fisher Scientific TXG 10X Genomics WAT Waters ZY Zymergen OMIC Singular Genomics Systems GH Guardant Health MYGN Myriad Genetics NEO NeoGenomics QTRX Quanterix Corp CTKB Cytek Biosciences HLTH Cue Health OLK Olink Holding AB ADR TX Ternium SA ADR CDNA Caredx MTD Mettler-Toledo International SMFR Sema4 Holdings Corp AVTR Avantor EXAS EXACT Sciences BRKR Bruker LMDX LumiraDx Ltd TWST Twist Bioscience Corp A Agilent Technologies DNA Ginkgo Bioworks Holdings QGEN Qiagen NV VCYT Veracyte PACB Pacific Biosciences of California CRL Charles River Laboratories ICLR ICON PLC IQV IQVIA Holdings FTRE Fortrea Holdings ADPT Adaptive Biotechnologies Corp NVT nVent Electric PLC RVTY Revvity SHC Sotera Health Co OCDX Ortho Clinical Diagnostics Holdings plc

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Apr-2025

$255

$25.96 (11.33%)

$230

15 days ago
(07-Oct-2026)

20/29 (68.97%)

$39.39 (18.27%)

214

Buy Since 23-Apr-2025

$250

$20.96 (9.15%)

$215

17 days ago
(05-Oct-2026)

16/23 (69.57%)

$28.79 (13.01%)

196

Buy Since 23-Apr-2025

$250

$20.96 (9.15%)

$200

21 days ago
(01-Oct-2026)

1/6 (16.67%)

$38.24 (18.06%)

16

Hold Since 30-Jan-2025

$195

$-34.04 (-14.86%)

$212

3 months ago
(22-Jul-2026)

15/20 (75%)

$16.18 (9.05%)

268

Buy Since 27-Jul-2020

$236

$6.96 (3.04%)

$240

3 months ago
(22-Jul-2026)

8/25 (32%)

$57.18 (31.98%)

259

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?